Genetic polymorphisms associated with venous thrombosis, methods of detection and uses thereof
View Patent ↗The present invention is based on the discovery of genetic polymorphisms that are associated with coronary heart disease and in particular VT and response to drug treatment. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.
1. A method for determining that a human has an increased risk for venous thrombosis, comprising detecting in nucleic acid from said human the presence of a homozygous C/C genotype at a polymorphism in gene RGS7 as represented by position 101 of SEQ ID NO: 172 or a homozygous G/G genotype at the complement of said position 101 of SEQ ID NO:172, and determining that said human has said increased risk for venous thrombosis.
2. The method of claim 1 , wherein said nucleic acid is a nucleic acid extract from a biological sample from said human.
3. The method of claim 2 , wherein said biological sample is blood, saliva, or buccal cells.
4. The method of claim 2 , further comprising preparing said nucleic acid extract from said biological sample prior to said detecting.
5. The method of claim 4 , further comprising obtaining said biological sample from said human prior to said preparing.
6. The method of claim 1 , wherein said detecting comprises nucleic acid amplification.
7. The method of claim 6 , wherein said nucleic acid amplification is carried out by polymerase chain reaction.
8. The method of claim 1 , wherein said detecting is performed using sequencing, 5′ nuclease digestion, molecular beacon assay, oligonucleotide ligation assay, size analysis, single-stranded conformation polymorphism (SSCP), or denaturing gradient gel electrophoresis (DGGE).
9. The method of claim 1 , wherein said detecting is performed using an allele-specific method.
10. The method of claim 9 , wherein said allele-specific method comprises allele-specific probe hybridization, allele-specific primer extension, or allele-specific amplification.
11. The method of claim 9 , wherein said testing is performed using an allele-specific primer comprising a sequence selected from the group consisting of SEQ ID NO:221, SEQ ID NO:222, and sequences fully complementary to SEQ ID NO:221 or 222.
12. The method of claim 1 which is an automated method.
13. A method for determining that a human has an increased risk for venous thrombosis, comprising:
a) testing nucleic acid from said human to determine the nucleotide content at a polymorphism in gene RGS7 as represented by position 101 of SEQ ID NO:172 or the complement of said position 101 of SEQ ID NO:172; and
b) correlating the presence of a homozygous C/C genotype at said position 101 of SEQ ID NO: 172 or a homozygous G/G genotype at said complement with said human having said increased risk for venous thrombosis.
14. The method of claim 13 , wherein said nucleic acid is a nucleic acid extract from a biological sample from said human.
15. The method of claim 14 , wherein said biological sample is blood, saliva, or buccal cells.
16. The method of claim 14 , further comprising preparing said nucleic acid extract from said biological sample prior to said testing.
17. The method of claim 16 , further comprising obtaining said biological sample from said human prior to said preparing.
18. The method of claim 13 , wherein said testing comprises nucleic acid amplification.
19. The method of claim 13 , wherein said nucleic acid amplification is carried out by polymerase chain reaction.
20. The method of claim 13 , wherein said testing is performed using sequencing, 5′ nuclease digestion, molecular beacon assay, oligonucleotide ligation assay, size analysis, single-stranded conformation polymorphism analysis, or denaturing gradient gel electrophoresis (DGGE).
21. The method of claim 13 , wherein said testing is performed using an allele-specific method.
22. The method of claim 21 , wherein said allele-specific method comprises allele-specific probe hybridization, allele-specific primer extension, or allele-specific amplification.
23. The method claim 21 , wherein said testing is performed using an allele-specific primer comprising a sequence selected from the group consisting of SEQ ID NO:221, SEQ ID NO:222, and sequences fully complementary to SEQ ID NO:221 or 222.
24. The method of claim 13 which is an automated method.
25. The method of claim 1 , wherein said venous thrombosis is deep vein thrombosis (DVT).
26. The method of claim 13 , wherein said venous thrombosis is deep vein thrombosis (DVT).